Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.

The CDE of China's NMPA has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second BTD.

The London Biotechnology Show 2025, held from 18 to 19 June, encompassed a range of sessions on automation, regulation, and ...

While the UK continues its close 25-year partnership with Gavi, the US is halting funding to the organisation. In a move that ...

The US FDA has granted approval for a label update to Eli Lilly and Company's Amyvid (florbetapir F 18 injection) for use ...

Novartis has completed its previously announced acquisition of Regulus Therapeutics for $1.7bn, strengthening its renal ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...